deltatrials
Terminated PHASE2 NCT00206492

Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients

A Neoadjuvant Phase II Trial of ZD1839 (Iressa) and Tamoxifen in Inoperable Locally Advanced HER2-Overexpressing, ER-Positive Breast Cancer Patients: Biologic Correlative Study (AZ #1839US/0303)

Sponsor: AstraZeneca

Conditions Breast Cancer
Interventions Iressa Tamoxifen
Updated 6 times since 2017 Last updated: Jul 28, 2017 Started: Jul 31, 2003 Primary completion: Oct 31, 2006 Completion: Oct 31, 2006

Listed as NCT00206492, this PHASE2 trial focuses on Breast Cancer and remains terminated or withdrawn. Sponsored by AstraZeneca, it has been updated 6 times since 2003, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

  5. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE2

    First recorded

Jul 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
  • Baylor Breast Care Center
Data source: Baylor Breast Care Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Houston, United States